»¶ÀÖ¶·µØÖ÷_Õ©½ð»¨ÓÎÏ·

QIN Bei, LIU Xiaohui, QIN Cheng

( Department of Ophthalmology, the Second Affiliated Hospital Guilin 

Medical College, Guilin 541199, China)

Abstract Objective To observe the clinical efficacy of Leizumab combined with 577 nm micropulse laser in the patients with non ischemic central retinal vein occlusion ( CRVO) and secondary macular edema ( ME) . Methods 34 patients with non-deficient CRVO and secondary ME were selected. Patients were divided into control group and observation group according to their choice of whether to receive micropulse laser therapy, with 17 cases ( 17 eyes) in each group. The control group were treated with intravitreal injection of Leizumab, and the observation group were treated with Leizumab combined with 577 nm micropulse laser. The best corrected visual acuity ( BCVA) , macular central retinal thickness ( CMT) , total injection times and pro re nata ( PRN) times were compared between the two groups 1 month, 3 months and 6 months after treatment. Results At 3 months and 6 months after treatment, BCVA in observation group was better than that in control group, CMT was lower than that in control group. The differences between the two groups were statistically significant ( all P<0.05) . The total injection times in the observation group was less than that in the control group ( P<0.05) . There was no significant difference in PRN times between the two groups ( P>0.05) . Conclusion Leizumab combined with 577 nm micropulse laser is effective in the treatment of non-ischemic CRVO and secondary ME, which can improve patients¡ä visual acuity, lower macular thickness and reduce the total injection times.

Keywords: non-ischemic central retinal vein occlusion; macular edema; ranibizumab; 577 nm micropulse laser

DOI:10.19296/j.cnki.1008-2409.2024-03-032

PDF download£ºclick to download